Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.7 EUR | -1.27% | -2.50% | -8.24% |
03-14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
03-14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 8.15M 8.71M 11.91M | Sales 2025 * | 11.95M 12.78M 17.47M | Capitalization | 328M 350M 479M |
---|---|---|---|---|---|
Net income 2024 * | -14M -14.97M -20.46M | Net income 2025 * | -18M -19.25M -26.31M | EV / Sales 2024 * | 38.8 x |
Net cash position 2024 * | 11.6M 12.4M 16.96M | Net Debt 2025 * | 7M 7.48M 10.23M | EV / Sales 2025 * | 28 x |
P/E ratio 2024 * |
-23.4
x | P/E ratio 2025 * |
-17.9
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.38% |
Latest transcript on Hyloris Pharmaceuticals SA
1 day | -1.27% | ||
1 week | -2.50% | ||
Current month | +2.18% | ||
1 month | +5.41% | ||
3 months | -10.34% | ||
6 months | -5.65% | ||
Current year | -8.24% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jacobsen
FOU | Founder | 50 | 11-12-31 |
Stijn van Rompay
FOU | Founder | 48 | 11-12-31 |
Director of Finance/CFO | 53 | 21-09-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carolyn Myers
BRD | Director/Board Member | 66 | 19-12-31 |
James Gale
BRD | Director/Board Member | 74 | 19-12-31 |
Leon van Rompay
BRD | Director/Board Member | 75 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 11.7 | -1.27% | 5,657 |
24-04-25 | 11.85 | -0.84% | 3,406 |
24-04-24 | 11.95 | +2.14% | 4,475 |
24-04-23 | 11.7 | -2.09% | 7,424 |
24-04-22 | 11.95 | -0.42% | 10,433 |
Real-time Euronext Bruxelles, April 26, 2024 at 11:37 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.24% | 350M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HYL Stock